Skip to content

EBIT at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$169M-18.2%
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
-$137.36M+5.6%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$44.96M-95.4%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$130.25M+12.2%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
-$82.77M-31.2%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS

Other financials

Income statement

See full
Revenue$3.6M+127%
Gross profit$3.3M+144%
Operating income-$45.7M-16.2%
Net income-$53.5M-22.7%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$140.0M-35.6%
Total debt$63.3M-4.3%
Total equity$149.3M+343%
Total assets$778.7M+28.6%

Cash flow

See full
Operating cash flow-$38.2M+13.3%
CapEx$140.0K+11.1%
Free cash flow-$38.4M+13.2%

Valuation

See full
Market cap$3.09B+78.4%
Enterprise value$3.02B+124%
P/S170.9×+85.1×

Profitability

See full
Gross margin90.6%-2.9pp
Operating margin-1,059.7%+380pp
Net margin-1,154.4%+89.3pp
FCF margin-953.7%+169pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.4×-1.5×
Current ratio10.4×-1.6×

Where this comes from

Calculated from uniQure’s reported figures.

The official record: uniQure’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about uniQure's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is uniQure's EBIT?
uniQure (QURE) reported EBIT of -$45.72M in Q1 2026.
How has uniQure's EBIT changed year-over-year?
uniQure's EBIT decreased by 16.2% year-over-year, from -$39.33M to -$45.72M.
What is the long-term trend for uniQure's EBIT?
Over 4 years (2021 to 2025), uniQure's EBIT has grown at a -12.1% compound annual growth rate (CAGR), from $310.62M to -$185.35M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.